Cancer cell lines are widely used as in vitro models of tumorigenesis, facilitating fundamental discoveries in cancer biology and
translational medicine. Currently, there are few options for glioblastoma (GBM) treatment and limited in vitro models with
accurate genomic and transcriptomic characterization. Here, a detailed characterization of a new GBM cell line, namely AHOL1,
was conducted in order to fully characterize its molecular composition based on its karyotype, copy number alteration (CNA),
and transcriptome profiling, followed by the validation of key elements associated with GBM tumorigenesis. Large numbers of
CNAs and differentially expressed genes (DEGs) were identified. CNAs were distributed throughout the genome, including
gains at Xq11.1-q28, Xp22.33-p11.1, Xq21.1-q21.33, 4p15.1-p14, 8q23.2-q23.3 and losses at Yq11.21-q12, Yp11.31-p11.2, and
15q11.1-q11.2 positions. Nine druggable genes were identified, including HCRTR2, ETV1, PTPRD, PRKX, STS, RPS6KA6,
ZFY, USP9Y, and KDM5D. By integrating DEGs and CNAs, we identified 57 overlapping genes enriched in fourteen pathways.
Altered expression of several cancer-related candidates found in the DEGs-CNA dataset was confirmed by RT-qPCR. Taken
together, this first comprehensive genomic and transcriptomic landscape of AHOL1 provides unique resources for further
studies and identifies several druggable targets that may be useful for therapeutics and biologic and molecular investigation of
GBM.
|
